{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:39:29Z","timestamp":1787017169883,"version":"build-2736575974"},"reference-count":58,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Camurus","award":["UK-NPR-2300062"],"award-info":[{"award-number":["UK-NPR-2300062"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Advances in the treatment of opioid use disorder (OUD) have seen the development of long-acting injectable opioid substitutes which could improve outcomes for people with OUD. However, comparative quantitative analysis of individual outcomes is lacking. The present study sought to investigate factors associated with prescribing long-acting injectable buprenorphine (LAIB), and changes in outcome variables compared with oral medication for OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional retrospective analysis of electronic health records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Community substance use treatment service Via. Six sites shared their data between 15 August 2022 and 15 August 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Anonymised data were extracted for 235 people receiving LAIB and 266 people receiving oral medication for OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes<\/jats:title>\n                    <jats:p>Prescribing data, sociodemographic information (age, sex, indices of multiple deprivation decile of individual\u2019s residence, primary and secondary substance, number of previous treatment episodes, employment and ethnicity) and treatment outcome profiles (substance use, physical and mental health, quality of life, employment) were extracted and analysed. To examine predictors of receiving LAIB (vs medication for OUD), we conducted logistic regression including the demographic predictors. Psychological health, physical health and quality of life scores were analysed using Welch\u2019s t-tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LAIB was associated with positive changes in quality of life between the first and last assessments. Demographic and situational factors were predictors of LAIB initiation, indicating the potential for increasing health inequalities in substance use treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LAIB is associated with changes in quality of life over a 1-year period. Further research is needed to investigate the aetiology of improved well-being and outcomes over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090736","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:20:43Z","timestamp":1739910043000},"page":"e090736","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-5807","authenticated-orcid":false,"given":"Catharine","family":"Montgomery","sequence":"first","affiliation":[{"name":"Liverpool John Moores University, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Via Community Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon","family":"De Silva","sequence":"additional","affiliation":[{"name":"Via Community Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Gittins","sequence":"additional","affiliation":[{"name":"Aston University, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jones","sequence":"additional","affiliation":[{"name":"Liverpool John Moores University, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-4060","authenticated-orcid":false,"given":"Marie-Claire","family":"Van Hout","sequence":"additional","affiliation":[{"name":"South East Technological University, Waterford, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025121409104595000_15.2.e090736.1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12551"},{"key":"2025121409104595000_15.2.e090736.2","unstructured":"Dydyk AM , Jain NK , Gupta M . Opioid use disorder. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553166\/"},{"key":"2025121409104595000_15.2.e090736.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.05.021"},{"key":"2025121409104595000_15.2.e090736.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.06.020"},{"key":"2025121409104595000_15.2.e090736.5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/d41586-019-02682-6","article-title":"Opioids by the numbers","volume":"573","author":"Drew","year":"2019","journal-title":"Nature New Biol"},{"key":"2025121409104595000_15.2.e090736.6","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121409104595000_15.2.e090736.7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000468518","article-title":"Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample","volume":"23","author":"Soyka","year":"2017","journal-title":"Eur Addict Res"},{"key":"2025121409104595000_15.2.e090736.8","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","volume":"10","author":"Amato","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121409104595000_15.2.e090736.9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","article-title":"Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder","volume":"14","author":"Crotty","year":"2020","journal-title":"J Addict Med"},{"key":"2025121409104595000_15.2.e090736.10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2515\/therapie:2003017","article-title":"Crit\u00e8res pharmacologiques d\u2019un m\u00e9dicament pour la substitution de la pharmacod\u00e9pendance aux opiac\u00e9s","volume":"58","author":"Montastruc","year":"2003","journal-title":"Therapies"},{"key":"2025121409104595000_15.2.e090736.11","doi-asserted-by":"publisher","DOI":"10.1111\/add.12536"},{"key":"2025121409104595000_15.2.e090736.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0094-5"},{"key":"2025121409104595000_15.2.e090736.13","unstructured":"National Academies of Sciences, Engineering, and Medicine . Medications for opioid use disorder save lives. Washington, DC: The National Academies Press, 2019."},{"key":"2025121409104595000_15.2.e090736.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"2025121409104595000_15.2.e090736.15","doi-asserted-by":"crossref","unstructured":"Gowing L , Farrell MF , Bornemann R , et al . Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011;CD004145. doi:10.1002\/14651858.CD004145.pub4","DOI":"10.1002\/14651858.CD004145.pub4"},{"key":"2025121409104595000_15.2.e090736.16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00335.x"},{"key":"2025121409104595000_15.2.e090736.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: A systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"key":"2025121409104595000_15.2.e090736.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"key":"2025121409104595000_15.2.e090736.19","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2025121409104595000_15.2.e090736.20","article-title":"Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life","volume":"13","author":"Somaini","year":"2021","journal-title":"Cureus"},{"key":"2025121409104595000_15.2.e090736.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108651","article-title":"Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective","volume":"221","author":"Hall","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121409104595000_15.2.e090736.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108221","article-title":"Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges","volume":"124","author":"Arunogiri","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2025121409104595000_15.2.e090736.23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.therap.2020.05.007","article-title":"Prolonged-release buprenorphine formulations: Perspectives for clinical practice","volume":"75","author":"Chappuy","year":"2020","journal-title":"Therapie"},{"key":"2025121409104595000_15.2.e090736.24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5498\/wjp.v11.i9.543","article-title":"Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations","volume":"11","author":"Soyka","year":"2021","journal-title":"World J Psychiatry"},{"key":"2025121409104595000_15.2.e090736.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"2025121409104595000_15.2.e090736.26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025121409104595000_15.2.e090736.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106756","article-title":"Long-acting buprenorphine injectables: Opportunity to improve opioid use disorder treatment among rural populations","volume":"152","author":"Lofwall","year":"2021","journal-title":"Prev Med"},{"key":"2025121409104595000_15.2.e090736.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121409104595000_15.2.e090736.29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104002","article-title":"\u201cI just thought that was the best thing for me to do at this point\u201d: Exploring patient experiences with depot buprenorphine and their motivations to discontinue","volume":"115","author":"Clay","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2025121409104595000_15.2.e090736.30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","volume":"111","author":"Saunders","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"2025121409104595000_15.2.e090736.31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","article-title":"Opioid users\u2019 willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","volume":"104","author":"Tompkins","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2025121409104595000_15.2.e090736.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025121409104595000_15.2.e090736.33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management","volume":"94","author":"Kenney","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2025121409104595000_15.2.e090736.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108316"},{"key":"2025121409104595000_15.2.e090736.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108492","article-title":"Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone","volume":"220","author":"Rolland","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121409104595000_15.2.e090736.36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/add.14941","article-title":"Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia","volume":"115","author":"Larance","year":"2020","journal-title":"Addiction"},{"key":"2025121409104595000_15.2.e090736.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108776","article-title":"Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health","volume":"139","author":"Martin","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025121409104595000_15.2.e090736.38","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2025121409104595000_15.2.e090736.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102311","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","volume":"66","author":"Marsden","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025121409104595000_15.2.e090736.40","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1192\/bjo.2023.244","article-title":"Systematic Review of the Safety and Tolerability of Injectable Prolonged-Release Buprenorphine (Buvidal) in Adults With Opioid Dependence","volume":"9","author":"Williams","year":"2023","journal-title":"BJPsych open"},{"key":"2025121409104595000_15.2.e090736.41","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/10826084.2024.2392553","article-title":"Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients\u2019 Interpersonal Relationships during the First Year of Treatment","volume":"59","author":"Neale","year":"2024","journal-title":"Subst Use Misuse"},{"key":"2025121409104595000_15.2.e090736.42","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study","volume":"13","author":"Ling","year":"2019","journal-title":"J Addict Med"},{"key":"2025121409104595000_15.2.e090736.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.11.004"},{"key":"2025121409104595000_15.2.e090736.44","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-023-01348-5","article-title":"Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study","volume":"9","author":"Hard","year":"2023","journal-title":"Pilot Feasibility Stud"},{"key":"2025121409104595000_15.2.e090736.45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/SAR.S266838","article-title":"Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine","volume":"11","author":"Parsons","year":"2020","journal-title":"Subst Abuse Rehabil"},{"key":"2025121409104595000_15.2.e090736.46","unstructured":"UK Addiction Treatment . Addiction Treatment Budget Cuts by Local Authority, 2024. Available: https:\/\/www.ukat.co.uk\/addiction-treatment-budget-cuts\/"},{"key":"2025121409104595000_15.2.e090736.47","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-013-9341-3"},{"key":"2025121409104595000_15.2.e090736.48","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700315"},{"key":"2025121409104595000_15.2.e090736.49","unstructured":"The Department of Health\u2019s Black and Minority Ethnic Drug Misuse Needs Assessment Project, Available: https:\/\/www.lwl.org\/ks-download\/downloads\/searchII\/report_GB_2.pdf"},{"key":"2025121409104595000_15.2.e090736.50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/CEOR.S242984","article-title":"Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements","volume":"12","author":"Phillips-Jackson","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025121409104595000_15.2.e090736.51","unstructured":"Mahto A . splitstackshape: Stack and Reshape Datasets After Splitting Concatenated Values. R package version 1.4.8. 2019. Available: https:\/\/CRAN.R-project.org\/package=splitstackshape"},{"key":"2025121409104595000_15.2.e090736.52","unstructured":"Office for Health Improvement and Disparities: Treatment Outcome Profiles . Treatment outcomes profile (secure setting), Available: https:\/\/www.ndtms.net\/resources\/public\/Event%20and%20Training%20Documentation\/CDSQ%20combined%20review%20and%20outcome%20forms\/Adult%20secure%20estate%20TOP%20form%20CDSQ%20v1.pdf"},{"key":"2025121409104595000_15.2.e090736.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02284.x"},{"key":"2025121409104595000_15.2.e090736.54","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"2025121409104595000_15.2.e090736.55","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2021.871","article-title":"Service evaluation of long acting buprenorphine subcutaneous injection (BUVIDAL) in the west Lothian community addictions service","volume":"7","author":"Martin","year":"2021","journal-title":"BJPsych Open"},{"key":"2025121409104595000_15.2.e090736.56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jagp.2021.02.039","article-title":"Heroin Use in Older Adults: A Treatment Challenge","volume":"29","author":"Mannelli","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"key":"2025121409104595000_15.2.e090736.57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2017.10.007","article-title":"Treatment for opioid use and outcomes in older adults: a systematic literature review","volume":"182","author":"Carew","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025121409104595000_15.2.e090736.58","unstructured":"British National Formulary . Substance Dependence: Guidance on treatment of drug misuse; Opioid Dependence, 2017. Available: https:\/\/bnf.nice.org.uk\/treatment-summaries\/substance-dependence"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:11:00Z","timestamp":1765732260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,18]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-090736"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090736","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}